NYU launching $10M Center for Psychedelic Medicine in Manhattan
Marijuana Stocks, Finance, & InvestingUncategorized February 26, 2021 MJ Shareholders
New York University wants to expand our minds — but in a trippy new way.
NYU Langone Health’s Department of Psychiatry plans to establish a Center for Psychedelic Medicine, a hallucinatory hub that will support research on treating addiction, chronic pain, opioid addiction and “existential distress” — among other physical and emotional maladies — using psychedelics. NYU researchers are already involved in studies on the treatment of alcoholism, anxiety and major depressive disorder with psilocybin (the active ingredient in magic mushrooms) and the treatment of severe PTSD with MDMA (also known as ecstasy and molly).
The program, announced Wednesday, will also be the home base for NYU’s new Psychedelic Medicine Research Training Program, which will attempt to make psychedelic medicine more mainstream and increase the number of experts in the field.
Read More
MJ Shareholders
MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers
